MDGL (madrigalpharma.com) Rasio Nilai Pasar marang Nilai Buku

Simbol resmi perusahaan Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals (MDGL) possesses exceptional pricing power due to its first-mover advantage in MASH therapy. High clinical trial costs and patent protection create formidable barriers to entry for competitors. The company is tapping into a massive market for metabolic pathologies while maintaining a temporary monopoly. The dynamics of market capitalization relative to the balance sheet clearly demonstrate the current trend, with the value 19.60 capturing this metric.

MDGL Madrigal Corp: Nilai Pasar marang Nilai Buku ing interval 04.07.2022 - 28.10.2026

Rincian metrik keuangan lan pasar Madrigal Pharmaceuticals Inc (MDGL)

- rega lan prakiraan konsensus rega:
Bagan rega Madrigal Pharmaceuticals|MDGL - Bagan rega target
- data kapitalisasi pasar:
Nilai pasar Madrigal Pharma|MDGL - Nilai Wutuh Bisnis
- data kapitalisasi buku:
Nilai Buku saben Saham Madrigal Pharmaceuticals|MDGL - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku madrigalpharma.com|MDGL - Total Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas Madrigal Pharmaceuticals|MDGL - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Madrigal Pharma|MDGL - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Madrigal Pharma|MDGL - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Madrigal Pharmaceuticals
Analisis wiwitan perusahaan:Madrigal Pharmaceuticals - MDGL
Produk asli Madrigal Pharma

Investors in Madrigal Pharmaceuticals (MDGL) face a choice between growth potential and the risk of overpaying for uncertain future earnings. The market-to-book premium captures the gap between the market price and tangible assets, reflecting the extent of expectations priced in for its first-mover status in liver therapy amid pressure from competing pharma behemoths.

Pesaing utama

Ascendis Pharma A/S (ASND) - Rasio Nilai Pasar marang Nilai Buku|CORT (corcept.com) - Rasio Nilai Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Rhythm Pharmaceuticals, Inc. RYTM|Kapitalisasi Pasar marang Aset Bersih Akero Therapeutics, Inc.|Metsera Corp (MTSR) - Rasio Kapitalisasi Pasar marang Nilai Buku|Nilai Pasar marang Nilai Buku MoonLake Corp (MLTX)|Rasio Kapitalisasi Pasar marang Nilai Buku CRNX (Crinetics Pharmaceuticals)|newamsterdampharma.com - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Soleno Therapeutics, Inc. (SLNO)|FOLD: Nilai Pasar marang Nilai Buku|ETNB (89bio Corp) - Rasio Nilai Pasar marang Nilai Buku|Agios Corp (AGIO) - Rasio Kapitalisasi marang Aset Bersih|GPCR (Structure Therapeutics) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku mimedx.com (MDXG)|Rezolute (RZLT) - Rasio Kapitalisasi marang Aset Bersih|Nilai Pasar marang Nilai Buku LXRX (Lexicon Pharmaceuticals Inc)|MBX Bio - Rasio Nilai Pasar marang Nilai Buku|Rasio Kapitalisasi marang Aset Bersih Altimmune Pharma ALT|AARD (Aardvark Therapeutics Inc) - Rasio Kapitalisasi Pasar marang Nilai Buku|sagimet.com (SGMT) - Koefisien Nilai Pasar marang Nilai Buku|BIOA - Rasio Kapitalisasi marang Aset Bersih|Biomea Fusion Inc (BMEA) - Multiplikator Kapitalisasi Pasar marang Nilai Buku|QNCX (Quince Therapeutics Inc) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku Fractyl Health, Inc|Rasio Kapitalisasi Pasar marang Nilai Buku vTv Therapeutics Inc. (VTVT)|Rasio Nilai Pasar marang Nilai Buku ATPC (agapeatpgroup.com)|PLUR: Rasio Nilai Pasar marang Nilai Buku|Synlogic Inc. - Koefisien Nilai Pasar marang Nilai Buku|LPCN - Rasio Nilai Pasar marang Nilai Buku|MTNB - Rasio Nilai Pasar marang Nilai Buku|Spruce Biosciences - Rasio Kapitalisasi Pasar marang Nilai Buku|GLTO (galecto.com) - Kapitalisasi Pasar marang Nilai Buku|CTCX: Rasio Nilai Pasar marang Nilai Buku|Kapitalisasi Pasar marang Nilai Buku LUMO|Rasio Nilai Pasar marang Nilai Buku ONVO (Organovo Holdings Inc)|Rasio Kapitalisasi marang Aset Bersih RDUS (Radius Pharmaceuticals)